“Liquid elbows” due to afatinib administration

Non-small cell lung cancer adenocarcinoma in the past decade has targeted therapies as the cornerstone for therapy. In specific patients with epidermal growth factor receptor mutation have three different therapy approaches with the tyrosine kinase inhibitors: erlotinib, gefitinib and afatinib. Nowadays we can use tyrosine kinase inhibitors as second line treatment for squamous cell carcinoma. We present a case with a patient with squamous cell carcinoma receiving afatinib tyrosine kinase inhibitor who presented elbow bursitis or olecranon bursitis in both elbows.

• Publication year

  2017

• Venue

  Respiratory Medicine Case Reports

• Publication date

  2017-06-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rmcr.2017.06.013PMID 28702338PMCID 5491760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

  2018cited by this paper
• Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?

  2017cited by this paper
• Pembrolizumab for the treatment of non-small cell lung cancer

  2017cited by this paper
• Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

  2017cited by this paper
• New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

  2017cited by this paper
• Second-line afatinib administration in an elderly patient with squamous cell carcinoma

  2017cited by this paper
• Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.

  2016cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy

  2013cited by this paper
• Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy.

  2013cited by this paper
• Treatment of non-small cell lung cancer (NSCLC).

  2013cited by this paper

• Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

  2020cites this paper
• Inhaled Cisplatin for NSCLC: Facts and Results

  2019cites this paper
• Inhaled chemotherapy adverse effects: mechanisms and protection methods

  2019cites this paper
• Psoriatic arthritis due to nivolumab administration a case report and review of the literature

  2018cites this paper
• Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

  2017cites this paper